These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25663437)

  • 21. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro.
    Deissler HL; Busch C; Wolf A; Rehak M
    Sci Rep; 2022 Jul; 12(1):12493. PubMed ID: 35864147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.
    Papadopoulos N; Martin J; Ruan Q; Rafique A; Rosconi MP; Shi E; Pyles EA; Yancopoulos GD; Stahl N; Wiegand SJ
    Angiogenesis; 2012 Jun; 15(2):171-85. PubMed ID: 22302382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
    Peng S; Adelman RA; Rizzolo LJ
    Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3216-25. PubMed ID: 20042644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
    Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
    Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of MAPKs in endostatin-mediated regulation of blood-retinal barrier function.
    Campbell M; Collery R; McEvoy A; Gardiner TA; Stitt AW; Brankin B
    Curr Eye Res; 2006 Dec; 31(12):1033-45. PubMed ID: 17169842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sitagliptin and the Blood-Retina Barrier: Effects on Retinal Endothelial Cells Manifested Only after Prolonged Exposure.
    Jäckle A; Ziemssen F; Kuhn EM; Kampmeier J; Lang GK; Lang GE; Deissler H; Deissler HL
    J Diabetes Res; 2020; 2020():2450781. PubMed ID: 32566677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells.
    Arnott C; Punnia-Moorthy G; Tan J; Sadeghipour S; Bursill C; Patel S
    PLoS One; 2016; 11(3):e0150688. PubMed ID: 26959822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome.
    Scotti L; Abramovich D; Pascuali N; Irusta G; Meresman G; Tesone M; Parborell F
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():392-401. PubMed ID: 25151950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
    Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
    Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes.
    Wisniewska-Kruk J; Hoeben KA; Vogels IM; Gaillard PJ; Van Noorden CJ; Schlingemann RO; Klaassen I
    Exp Eye Res; 2012 Mar; 96(1):181-90. PubMed ID: 22200486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quercetin inhibits vascular endothelial growth factor-induced choroidal and retinal angiogenesis in vitro.
    Li F; Bai Y; Zhao M; Huang L; Li S; Li X; Chen Y
    Ophthalmic Res; 2015; 53(3):109-16. PubMed ID: 25676100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impairment of the Retinal Endothelial Cell Barrier Induced by Long-Term Treatment with VEGF-A
    Deissler HL; Rehak M; Wolf A
    Biomolecules; 2022 May; 12(5):. PubMed ID: 35625661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins].
    Lang GE; Lang GK; Deissler HL
    Klin Monbl Augenheilkd; 2015 Mar; 232(3):295-302. PubMed ID: 25393440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells.
    Kalishwaralal K; Banumathi E; Ram Kumar Pandian S; Deepak V; Muniyandi J; Eom SH; Gurunathan S
    Colloids Surf B Biointerfaces; 2009 Oct; 73(1):51-7. PubMed ID: 19481908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of the Wnt Pathway in VEGF/Anti-VEGF-Dependent Control of the Endothelial Cell Barrier.
    Li Y; Baccouche B; Olayinka O; Serikbaeva A; Kazlauskas A
    Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):17. PubMed ID: 34542556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
    Lowe J; Araujo J; Yang J; Reich M; Oldendorp A; Shiu V; Quarmby V; Lowman H; Lien S; Gaudreault J; Maia M
    Exp Eye Res; 2007 Oct; 85(4):425-30. PubMed ID: 17714704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents--on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)].
    Golik P; Tońska K
    Klin Oczna; 2012; 114(1):79-83. PubMed ID: 22783753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetes-induced superoxide anion and breakdown of the blood-retinal barrier: role of the VEGF/uPAR pathway.
    El-Remessy AB; Franklin T; Ghaley N; Yang J; Brands MW; Caldwell RB; Behzadian MA
    PLoS One; 2013; 8(8):e71868. PubMed ID: 23951261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.